Rheumatoid Arthritis Clinical Trial
Aim: To describe 1) The use of TNF blockers in early arthritis in daily clinical practice in
France 2) To evaluate symptomatic, structural efficacy, and retention rate over 5 years 3)
To evaluate predictive factors for TNF blocker response Type of study: Observational cohort
study using cross-section and longitudinal data.
Description of the project methodology
- Patients: All patients in the ESPOIR cohort (multicentre French cohort study of early
RA).A sub-analysis will be conducted among patients satisfying the ACREULAR 2010
criteria.
- Data collected: Patient characteristics, Clinical data regarding RA and related
pathologies, Characteristics of treatments received The analysis will be conducted
using data collected at baseline, 6, 12, 18, 24, 36, 48, 60 months.
- Analyses:
1. Frequency of use of TNF blockers: the % of patients initiating TNF blockers will
be calculated (Kaplan-Meier method), and the type of TNF blocker will be
described, the route of administration, the dosage, the association with other
DMARDs and the place of the TNF blockers in the treatment strategy during the
first 5 years.
2. Implementation of EULAR recommendations: the percentage of patients that initiate
TNF blockers meeting the EULAR criteria for initiation will be estimated, and the
concordance coefficient Kappa with regard to such fulfilment and the initiation of
TNF blockers will be calculated, and disease severity outcome measures will be
compared depending on the fulfilment or not.
3. Identification of potential predictive factors for initiation of TNF blockers: a
survival curve (Kaplan-Meier) will be performed. The baseline characteristics of
the patients with regard to the initiation of TNF blocker during the first 5 years
of the disease will be compared by univariate analysis and Log-rank test will be
performed in all variables. A stepwise multivariate analysis (Cox analysis) will
be performed.
4. Therapeutical effect:the retention rate over time will be calculated, the changes
in different variables will be compared in the group of patients who have received
TNF blockers matched (using a propensity score) to 1,2 or 3 patients who have not.
The DAS28 and HAQ will be assessed and compared at the short term (after at least
8 weeks of treatment) and long term (last available visit) in groups. The
structural efficacy was evaluated by the radiographic progression at last
available visit.The drug effect will be identically estimated depending on the TNF
blocker used, by calculating the retention rate and comparing DAS28 at short term
and long term.
6) Identification of predictive factors for TNF blocker response: To evaluate the
impact of baseline demographics and disease conditions on the DAS28 and HAQ response
during the first 5 years will be compared by univariate and multivariate analysis.
Expected results:
Increase knowledge on the optimal use of TNF blocker and on predictive factors for TNF
blocker response in early RA patients.
n/a
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |